Trattamento

Experimental 480Vd (CC-92480, bortezomib and dexamethasone):

CC-92480

• Specified dose on specified days
• Other Names:
  • BMS-986348
  • Mezigdomide

Bortezomib

• Specified dose on specified days
• Other Names:
  • Velcade
  • BTZ

Dexamethasone

• Specified dose on specified days
• Other Names:
  • Decadron
  • Dex

Experimental: PVd (pomalidomide, bortezomib and dexamethasone):
Pomalidomide

• Specified dose on specified days
• Other Names:
  • Pomalyst
  • Imnovid
  • Pom

Bortezomib

• Specified dose on specified days
• Other Names:
  • Velcade
  • BTZ

Dexamethasone

• Specified dose on specified days
• Other Names:
  • Decadron
  • Dex

Obiettivo Principale

Progression-free Survival (PFS) [ Time Frame: From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years) ]

Criteri di inclusione

• Participant has documented diagnosis of MM and measurable disease, defined as any of the following:
  • • M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or
    • M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP)
    • For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.

  • Participants received 1 to 3 prior lines of antimyeloma therapy.
  • Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.

  Criteri di esclusione

  Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor.

  • • • For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.
      • Participant has had prior treatment with CC-92480 or pomalidomide.

  Other protocol-defined criteria apply.